Skip to Main Content

Covid-19 has underscored the critical role the biopharma industrial base plays in the U.S.’s national and economic security. As I write this, safe and effective Covid-19 vaccines that were developed in record time are protecting and saving lives and making it possible for people to return to the office, school, and travel — normal life, in other words.

In January 2018, STAT reporter Helen Branswell wrote a story that posed a worrisome question: “Who will answer the call in the next outbreak?” She recognized the risk to fragile partnerships between U.S. government agencies and the biopharmaceutical companies that had answered the call to a series of outbreaks, epidemics, and pandemics over a 15-year period, including West Nile, severe acute respiratory syndrome (SARS), the H1N1 pandemic, Middle East respiratory syndrome (MERS), H7N9 influenza, Ebola virus disease, and Zika.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

Create a display name to comment

This name will appear with your comment